Nivolumab plus chemo and immune drug for unresectable liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Phase 1/2 trial tests whether nivolumab combined with fluorouracil and interferon alpha can treat fibrolamellar liver cancer that cannot be safely removed with surgery. It aims to shrink or control the cancer and to see how safe the combination is.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or your legal guardian) can sign consent, and if under 18 you can assent too
- Your diagnosis is confirmed fibrolamellar hepatocellular carcinoma (FLHCC)
- Your cancer is not removable by surgery, but you may have disease outside the liver
- You have at least one measurable tumor area (meeting size cutoffs on CT/MRI or standard scans)
- Your blood counts and liver/kidney labs are within required limits, including good liver function (Child-Pugh A)
- You can safely take study treatment based on overall health and immune/autoimmune factors (no major uncontrolled conditions)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs, nivolumab and ipilimumab, as a first treatment for liver cancer that cannot be removed by surgery or has come back after local treatments.
This study tests a new way of giving immunotherapy drugs for advanced liver cancer that cannot be removed by surgery. The goal is to find the best dose for each patient, which may help control the cancer with fewer side effects.
This trial tests a combination of three treatments—chemo given directly into the liver, an oral targeted therapy, and an immunotherapy—for people with liver cancer that could be removed by surgery but isn't the first choice right now. The goal is to see if this combination can shrink the tumor and improve outcomes before surgery.
This study tests a new vaccine (a shot that may help your immune system attack cancer cells) combined with a glutamine-blocking drug (DRP-104) and two immunotherapy drugs (nivolumab and ipilimumab) for advanced fibrolamellar carcinoma. It aims to see if this combination can shrink tumors or slow their growth.
This Phase 1 trial tests a personalized peptide vaccine (targeting the DNAJB1-PRKACA fusion) combined with immunotherapy drugs to treat fibrolamellar hepatocellular carcinoma (FLC) or other eligible non-FLC cancers with the same gene fusion. It aims to see whether this immune-based treatment can shrink tumors and improve outcomes safely.
This trial tests a combination of treatments for liver cancer that cannot be removed with surgery. The treatments include a targeted therapy pill, a procedure that cuts off blood supply to the tumor, and radiation, plus an immunotherapy drug that helps your immune system fight the cancer. This approach aims to shrink tumors and improve outcomes.
Hear when a new Stage III Hepatocellular Carcinoma AJCC v8 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.